{
    "nctId": "NCT05744557",
    "briefTitle": "Vapocoolant Analgesia for Breast Lymphoscintigraphy",
    "officialTitle": "Vapocoolant Analgesia for Breast Lymphoscintigraphy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Any adult patient undergoing asubareolar breast lymphoscintigraphy injection will be eligible.\n* Age \u226518 years old\n* Ability to understand and the willingness to sign a written informed consent document.\n* Childbearing potential, lactating, pregnant women will be included.\n\nExclusion Criteria:\n\n* Patients who have allergy or had prior hypersensitivity to either of the vapocoolants including 1,1,1,3,3 Pentafluoropropane and 1,1,1,2-Tetrafluoroethane.\n* Patients with uncontrolled intercurrent illness (insulin dependent and non-insulin dependent diabetes)\n* Patients with psychiatric illness/social situations that would limit compliance with study requirements.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}